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Abstract
Background: Higher levels of circulating 25-Hydroxyvitamin D (25(OH)D) are associated with 
longer survival in several cancers, but the results have differed across cancer sites. The association 
between serum 25(OH)D levels and overall survival (OS) time in esophageal adenocarcinoma 
(EA) remains unclear.
Methods: We utilized serum samples from 476 patients with primary EA, recruited from 
Massachusetts General Hospital between 1999 and 2015. We used logrank tests to test the 
difference in survival curves across quartiles of 25(OH)D levels and extended Cox modeling to 
estimate adjusted hazard ratios (HR). We tested for interactions between clinical stage or BMI on 
the association between 25(OH)D and overall survival. We additionally performed sensitivity 
analyses to determine if race or timing of blood draw (relative to treatment) affected these results.
Results: We found no evidence that survival differed across quartiles of 25(OH)D (logrank 
p=0.48). Adjusting for confounders, we found no evidence the hazard of death among the highest 
quartile of 25(OH)D (Quartile 1) differed from any other quartile (Quartile2 HR 0.90, 95% 
Confidence Interval (CI) 0.67–1.23; Quartile3 HR 1.03, 95% CI 0.76–1.38; Quartile4(lowest) HR 
0.98, 95% CI 0.72–1.33). Sensitivity analyses yielded consistent results when accounting for race 
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or time between diagnosis and blood draw. Moreover, we did not find evidence of interaction 
between 25(OH)D and clinical stage or BMI on OS.
Conclusions: Serum level of 25(OH)D near time of diagnosis was not associated with OS in EA 
patients.
Impact: Screening 25(OH)D levels among EA patients at diagnosis is not clinically relevant to 
their cancer prognosis based on present evidence.
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Introduction
Esophageal adenocarcinoma is the predominant subtype of esophageal cancer in western 
countries, with increasing incidence over the last five decades, particularly in White men.(1–
6) Esophageal adenocarcinoma remains a deadly disease with an average 5-year survival of 
less than 20%.(2) The current best predictor of esophageal adenocarcinoma survival time is 
clinical stage at diagnosis.(1,2) Yet, even half of patients with stage I disease at diagnosis do 
not survive past five years.(2) Few, if any, modifiable factors are known to improve 
prognosis after diagnosis. Thus, markers of prognosis, especially modifiable factors, are in 
high demand to identify both patients at risk of poor clinical outcomes and interventions that 
can improve patient outcomes.
Recently, in vitro and in vivo studies of the vitamin D pathway have demonstrated its 
oncosupressive effects, including regulating pathways that inhibit proliferation, 
angiogenesis, and inflammation as well as pathways that promote cell adhesion and induce 
apoptosis.(7–11) Hypothetically, if the downstream metabolite of vitamin D, [1,25(OH) 2D], 
directly regulates oncosuppressive cell signaling, then more intake of vitamin D should 
generate more downstream regulation and have a protective effect on the development and 
progression of cancer. With supplements that are cheap and readily available, vitamin D 
makes a particularly attractive potential intervention. This, coupled with the biologically 
plausible mechanism, has generated widespread interest in the role of the vitamin D pathway 
in cancer initiation and progression.
Clinically and in epidemiological studies, 25-hydroxyvitamin D [25(OH)D], an upstream 
serum-circulating metabolite, reflective of both sun exposure and dietary intake (8,12), is 
used as a marker of bioavailable vitamin D because it is more stable and consistently 
measured over time compared to 1,25(OH)2D. Meta-analyses suggest that higher circulating 
25(OH)D at diagnosis and vitamin D supplementation both protect against total cancer-
specific mortality.(13–15) A large Mendelian randomization study of genetic variants in two 
genes (CYP2R1 and DHCR7) affecting plasma 25(OH)D levels also showed that genetically 
low 25(OH)D was associated with increased risk of total cancer mortality.(16) However, the 
results linking circulating 25(OH)D to cancer survival in specific cancer sites and across 
sites have been inconsistent.(17)
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Higher serum 25(OH)D levels at diagnosis have been associated with longer overall survival 
in colorectal cancer, lung, pancreatic, breast, melanoma, and prostate cancer, among others 
(17–27), but null findings have also been reported in studies of these same cancer sites.(28–
35) One recent study looked at the effect of 25(OH)D levels in esophageal cancer patients, 
half of whom had adenocarcinoma, and found no association with overall survival, but the 
blood was drawn on average 6 years before cancer diagnosis.(36) The role of circulating 
25(OH)D at time of diagnosis on survival in esophageal adenocarcinoma is not established. 
There may be true variability in the effect of vitamin D on prognosis across cancer sites due 
to unique tumor biology at different cancer sites, or the effect of vitamin D on survival may 
be modified by cancer stage (18,37–39), subtype(40), or by other metabolic factors in 
patients, such as obesity. These potential effect modifiers may be contributing to the modest 
reproducibility of results of the same cancer site across studies.
In this study, we tested whether higher levels of circulating 25(OH)D are associated with 
better overall survival among patients with esophageal adenocarcinoma. We additionally 
examined possible effect modification by clinical stage at diagnosis and BMI at diagnosis. 
Finally, we included several sensitivity analyses to assess whether timing of blood draw or 
race impacted our findings.
Methods
Study Population
The ongoing Molecular Epidemiology of Esophageal Cancers study consists of esophageal 
cancer patients recruited from Massachusetts General Hospital (Boston, MA) since January 
1999.(41,42) Patients were >18 years of age with histologically confirmed diagnosis. All 
patients provided written informed consent prior to study participation. At the time of 
enrollment, a trained interviewer obtains patients’ demographic and lifestyle information via 
baseline questionnaire. The study is conducted in accordance with recognized ethical 
guidelines was approved by the institutional review board at MGH and Harvard T.H. Chan 
School of Public Health. We used electronic medical records to determine patients’ clinical 
variables, including histology, treatment regimen, cancer stage, and relevant dates. The study 
population for this analysis was restricted to participants with histologically confirmed 
esophageal adenocarcinoma who were recruited at the time of their primary diagnosis 
between 1999 and September 2015 (N=587), which was when serum samples were sent for 
analysis. For this analysis, we excluded patients who were recruited at the time of cancer 
recurrence or cancer remission, who had a concurrent cancer, who only presented to MGH 
for a second opinion, or who were diagnosed with stage 0 disease. Of the eligible patient 
participants, 495 patients had serum samples available for analysis, and 476 patients with 
complete information on all confounders who were included in the analyses (Figure 1).
Vitamin D collection and measurement
When patients provided serum samples, the samples were stored at 4°C until processing and 
were processed within 24 hours of blood draw. Serum was isolated by centrifugation at 2000 
r.p.m. for 10min at 4°C. Serum samples were then aliquoted and stored in −80°C freezers. In 
the fall of 2015, serum levels of 25(OH)D were sent in two batches, seven weeks apart, to be 
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measured in the laboratory of Dr. Bruce Hollis (Medical University of South Carolina) by 
radioimmunoassay method.(12,43) We randomly selected and included blinded within-batch 
duplicates (4% of samples) and between batch duplicates (5% samples) to be measured. 
Batch 1 had an intra-assay CV 9.3%, batch 2 had an intra-assay CV of 19.1%, and the 
between batch replicates had an inter-assay CV of 29.4%. Of the samples included in this 
analysis, 90% serum vitamin D levels were measured in Batch 1. Since serum levels of 
25(OH)D fluctuate due to seasonal variability in sun exposure, we generated quartiles of 
25(OH)D per month of blood draw. Simulations have shown that this adjustment reduces 
bias toward the null due to measurement misclassification without inducing bias away from 
the null, which can happen when adjusting for month of blood draw as a covariate in 
multivariable regression model.(44) We additionally modeled 25(OH)D by clinical cut 
points (<10ng/mL, 10–20ng/mL, 20–30ng/mL, 30–40ng/mL, and ≥40ng/mL) and 
continuously (ng/mL).
Outcome: overall survival
The outcome of interest in this study was overall survival, defined as the time from the date 
of blood draw until date of death or censored at date last known to be alive. We adjusted for 
the time between date of diagnosis and the date of blood draw. Data on outcome measures 
were collected from clinical records and hospital cancer registries.
Covariate collection and measurement
Cancer stage at diagnosis was defined by TNM staging system, where T refers to tumor size, 
N refers to lymph node status, and M refers to metastasis, for grouping esophageal 
adenocarcinoma into clinical stage I-IV and further categorized lymph node negative, lymph 
node positive, and metastatic. Date of diagnosis was considered date of pathology-confirmed 
cancer. In this study, treatment regimen was modeled as a series of binary variables: 
chemotherapy (yes/no), radiation (yes/no), and surgery (i.e. esophagectomy) (yes/no), with 
surgery modeled as a time-dependent covariate. We chose to model surgery as time-
dependent for several reasons. First, the timing of the operation is related to cancer 
prognosis up to the point of surgery. Patients with early stage tumors receive 
esophagectomies as their first treatment whereas locally advanced patients will receive 
esophagectomies pending their response to chemotherapy and/or radiation treatment. 
Second, the successful completion of the procedure is the most beneficial form of treatment 
for esophageal adenocarcinoma patients and one of the best clinical indicators of prognosis. 
Third, the esophagectomy procedure has a huge impact on patients’ diets and weight, and 
thus likely also affects their vitamin D levels. We did not have the date of chemotherapy or 
radiation initiation; therefore, we did not model chemotherapy or radiation as time-
dependent covariates. We adjusted for year of diagnosis as a continuous variable, to account 
for slight modifications to treatment protocols throughout the study period. We also adjusted 
for crude cigarette smoking history as an ordinal variable (never, former, current), age as a 
continuous variable, and sex as a dichotomous variable. BMI at diagnosis was calculated as 
weight at diagnosis(kg) divided by height squared(meters2). Once calculated, BMI was 
categorized into four groups: BMI<18.5, 18.5≤BMI<25, 25≤BMI<30, and BMI≥30 kg/m2.
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Statistical Analyses
Main Analyses—We visualized survival time curves between quartiles of serum 25(OH)D 
and clinical stage using Kaplan-Meier plots. Univariate differences in survival curves were 
tested using logrank tests. We used multivariable extended Cox regression models to 
estimate hazard ratios (HR) of death by quartiles of 25(OH)D, adjusting for sex, age at 
diagnosis, BMI, smoking history, year of diagnosis, treatment modality (chemotherapy, 
radiation, and/or surgery) with surgery modeled as a time-dependent covariate, and 
stratifying baseline hazard by stage at diagnosis. When estimating the continuous 
association of 25(OH)D, we included season of blood draw in the model. Interactions 
between serum levels of 25(OH)D quartiles and BMI categories (excluding underweight 
patients) and clinical stage at diagnosis were tested independently by adding interaction 
terms to the model, with significance tested by the joint Wald Test (BMI categories and 
25(OH)D quartiles with 6DF, and clinical stage with 25(OH)D quartiles with 6DF).
Sensitivity Analyses—Most participants’ blood samples were drawn close to the time of 
diagnosis, but many subjects had already initiated treatment at the time of serum draw. We 
suspected that chemotherapy, radiation, and especially surgical esophagectomy prior to 
blood draw could affect 25(OH)D levels at the time blood is drawn. Since we did not have 
the dates of first chemotherapy or radiation treatment, we could not account perfectly for the 
initiation of neoadjuvant or definitive chemotherapy and radiation treatment. However, we 
could determine how many weeks after diagnosis a patient’s blood was drawn, and when 
blood was drawn in relation to surgery (for those patients who had surgery). We then 
assumed among patients who received chemotherapy and radiation, those whose blood was 
drawn >=4 weeks after diagnosis likely had received some treatment, and patients whose 
blood was drawn <4 weeks after diagnosis had not initiated treatment yet. We then classified 
patients as having no treatment at the time of serum draw, having some chemotherapy and 
radiation treatment but no surgery at the time of serum draw, having had surgery within 12 
weeks of the serum draw, and having serum drawn ≥ 12 weeks after surgery (Supplementary 
Table 1). We tested mean differences in 25(OH)D levels between these groups using 
ANOVA, and we repeated our main analysis restricting to patients who had not received 
treatment at the time their serum was drawn.
As an additional sensitivity analysis, we crudely imputed 25(OH)D levels at the time of 
diagnosis. For this imputed analysis, we restricted our study population to subjects with 
25(OH)D levels with 3 standard deviations (SD) of the mean, and who had their blood 
drawn sometime within the week of their diagnosis up to one year past the date of diagnosis 
because the linear regression coefficient estimates might be unduly influenced by outliers. 
We additionally excluded those who were missing information about race, given the 
potential effect of skin pigmentation on vitamin D formation and circulating levels. Using 
this subpopulation, we generated a predictive linear regression model of serum 25(OH)D 
level as a function of time that included time between diagnosis and blood draw and adjusted 
for age at blood draw, sex, race, smoking status, month of blood draw, year of diagnosis, 
BMI, chemotherapy treatment, radiation treatment, and surgery (if surgery had occurred 
before blood draw). We then modeled the HR of the estimated diagnosis 25(OH)D level on 
overall survival.
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Though race, as a proxy for skin pigmentation, is expected to be associated with uptake of 
Vitamin D through sun exposure (45), >90% of our study population identified as White, 
and the remaining participants identified as a variety of races and ethnicities, with each 
group too small for meaningful statistical comparison. As a separate sensitivity analysis, we 
restricted our study population to patients who identified as non-Hispanic White to 
determine the potential effect of race on the effect of 25(OH)D and overall survival. All 
analyses were performed in SAS 9.4(SAS Institute Inc., Cary, NC). P-values were 
considered significant at an alpha-level of 0.05.
Results
Study population demographics
495 patients had a serum samples available for 25(OH)D level measurement. Median time to 
serum draw was 7.6 weeks after diagnosis (interquartile range: 2.3–15.7 weeks). Patients 
who did not have serum available were more likely to be female and were less likely to have 
metastatic disease at diagnosis than the group with serum available (Table 1). Of the 495 
patients with serum samples available, 476 patients had complete information for relevant 
covariates and were included in the analyses (Figure 1). The overall mean 25(OH)D level 
was 20.6 ng/mL. The mean 25(OH)D level from highest(Q1) to lowest(Q4) quartile 
accounting for month of blood draw were 32.4 ng/mL (SD 11.0), 22.3 ng/mL (SD 2.5), 17.3 
ng/mL (SD 2.8), and 10.8 ng/mL(SD 3.8). Median survival time (Kaplan-Meier) was 26.0 
months (95% Confidence Interval (CI) 22.6–29.2)
Serum 25(OH)D levels and overall survival
We found no difference in unadjusted overall survival time across quartiles of 25(OH)D 
levels (Figure 2; Logrank p=0.48; Q1(REF); Q2 HR=0.84, 95%CI 0.62–1.13; Q3 HR=0.89, 
95%CI 0.67–1.19; Q4 HR=1.03, 95%CI 0.77–1.38). After adjusting for potential 
cofounders, we found no association between the highest quartile of 25(OH)D compared to 
the other quartiles of 25(OH)D and overall survival (Table 2; global p=0.86), nor did we find 
an association between clinical cut points of 25(OH)D levels with overall survival (global 
p=0.32) or continuous 25(OH)D levels with overall survival (Table 2; HR=1.00; 95%CI 
0.99–1.01; p=0.47).
Serum 25(OH)D level and clinical stage interaction with overall survival
Mean 25(OH)D levels for lymph node negative (19.4 ng/mL ± 8.1), lymph node positive 
(20.7 ng/mL ± 9.4), and metastatic disease (22.4 ng/mL ± 12.4) at time of diagnosis did not 
differ significantly (ANOVA p=0.10). In the multivariable extended Cox model, no 
significant interaction was found between lymph node status at diagnosis and 25(OH)D 
levels on the association with overall survival (Table 3; Wald (DF=6), joint test of interaction 
term, p=0.87).
Serum 25(OH)D level and BMI interaction with overall survival
Mean 25(OH)D levels for patients with BMI at time of diagnosis <18.5 kg/m2 (15.8 ng/mL 
± 5.9), 18.5≤BMI<25 kg/m2 (20.8 ng/mL ± 10.1), 25≤BMI<30 kg/m2 (21.6 ng/mL ± 10.5), 
and BMI≥30 kg/m2 (19.3 ng/mL ± 8.5) did not differ significantly (ANOVA p=0.10). We 
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additionally ran a multivariable survival model that included the interaction terms for BMI 
categories, excluding underweight patients due to small numbers, and quartiles of vitamin D 
adjusted for month of blood draw and found no evidence to support BMI as a modifier of the 
effect of vitamin D quartile on overall survival (Table 4; Wald joint test of interaction 
term(DF=6), p=0.36).
Sensitivity analysis accounting for time of blood draw
Mean 25(OH)D levels differed among patients with no treatment at the time of serum draw 
(22.6 ng/mL ± 10.5), patients who some chemotherapy and radiation treatment but no 
surgery (20.7 ng/mL ± 9.8), patients whose serum was drawn <12 weeks after surgery (18.7 
ng/mL ± 9.1), and patients whose serum was drawn ≥ 12 weeks after surgery (20.3ng/mL 
± 8.4; ANOVA p=0.026).
Among the 108 patients without treatment at the time of serum draw, we found no 
association between overall survival and 25(OH)D modeled as quartiles or continuous 
(Supplementary Table 2). When considered by clinical cut points, serum levels <40 ng/mL 
of vitamin D were significantly associated with higher hazard of all-cause death, but there 
was not an obvious pattern of association across cut points, and the sample sizes for these 
categories were very small, so these results should be considered cautiously.
When we further crudely imputed patients’ 25(OH)D level at the time of diagnosis. We 
again did not see a significant association of the imputed diagnostic 25(OH)D levels on 
overall survival (Supplementary Table 3; p=0.30).
Sensitivity analysis restricting to White patients
We additionally repeated all analyses, restricting the population to patients who identified as 
non-Hispanic White. The results for all analyses did not differ from the models where we 
used all subjects (Supplementary Table 4).
Discussion
We did not find evidence that levels of serum 25(OH)D around diagnosis are associated with 
overall survival in esophageal adenocarcinoma patients. Nor did we find evidence that the 
association of 25(OH)D on overall survival in esophageal adenocarcinoma patients differs 
by stage at diagnosis or BMI at diagnosis. Though serum levels of 25(OH)D did appear to 
differ according to treatment status at the time of blood draw, treatment did not appear to 
alter the association between 25(OH)D levels and overall survival among esophageal 
adenocarcinoma patients.
To our knowledge, this is the first study that has assessed the association between diagnostic 
25(OH)D levels and overall survival exclusively among esophageal adenocarcinoma 
patients. A pathologic study noted that high expression of vitamin D receptor (VDR) is 
common in esophageal adenocarcinoma tissues as well as the precancerous Barrett’s 
esophagus tissues, but expression was rare in squamous cell carcinoma tissues, lending 
evidence that the pathway may be more relevant to the tumor biology in adenocarcinoma.
(46) Another recent study reported that tumor VDR expression was associated with longer 
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overall survival among esophageal adenocarcinoma patients.(47) At least one study in 
esophageal squamous cell carcinoma reported patients with >10ng/mL 25(OH)D at time of 
diagnosis had longer overall survival than those with <10ng/mL, but they did not clearly 
report if or how they adjusted for the effects of seasonal variability of blood draw.(48) More 
recently, a study from the European Prospective Investigation in Cancer and Nutrition 
prospective cohort examined circulating 25(OH)D3 levels from blood drawn many years 
before diagnosis of cancer on mortality among head and neck and esophageal cancer 
patients.(36) In the 147 esophageal cancer patients included in the analysis (approximately 
50% esophageal adenocarcinoma), they found no association between circulating 25(OH)D3 
levels and overall survival or cancer specific survival (36), consistent with our findings.
Human observational studies, Mendelian randomization studies, and RCTs have reported 
that low levels of vitamin D are associated with increased risk of total cancer mortality.
(13,14,16,49) Yet due to the unique biology of different cancers, we do not know whether 
the vitamin D pathway has the same prognostic impact in all cancer sites. There may also be 
a threshold effect of vitamin D. Several studies of various cancer sites have reported 
significantly shorter survival time among patients with very low levels of 25(OH)D 
(<12ng/mL) compared to patients with even moderate levels (≥12–20 ng/mL).(50–52) In our 
study, we found no evidence of association between overall survival and 25(OH)D, even at 
levels <10ng/mL, in the whole population. When looking only among patients who had not 
initiated treatment at the time of serum draw, we did see that levels <40ng/mL were 
associated with increased hazard of death. However, given the small sample sizes in these 
categories and extreme uncertainty of these estimates, coupled with the consistently null 
findings in other models, we cannot rule out that those associations are spurious.
Epidemiologic studies in lung and pancreatic cancers have reported differences by stage in 
the association of 25(OH)D level on overall survival.(18,37,38) Biologically, Vitamin D is 
thought to slow tumor growth and inhibit metastases, among other things, so we 
hypothesized that the association with 25(OH)D would be weaker among patients with 
metastatic disease. However, we found no evidence of interaction between 25(OH)D and 
clinical stage on overall survival in this population.
High BMI (>30kg/m2) is a known risk factor developing esophageal adenocarcinoma but 
associated with better prognosis after diagnosis.(53–56) BMI is also related to vitamin D, as 
vitamin D through sun exposure and diet can be stored in the fat cells of a person rather than 
being converted into circulating 25(OH)D. Thus people with more adiposity tend to have 
lower serum circulating 25(OH)D than someone with less body fat but the same intake of 
vitamin D.(57) We did not find evidence of BMI as an effect modifier in this study. In 
healthy individuals, BMI is an adequate measure of adiposity, but sick cancer patients 
potentially have underlying sarcopenia or cachexia, so low BMI may indicate low lean mass 
and not necessarily low adiposity. Thus, the relationship between BMI and vitamin D in 
esophageal adenocarcinoma survival may be more complex than we were able to capture 
here.
We acknowledge limitations to our study. First, we did not have information on EA-specific 
mortality, but due to the aggressive pattern of EA, we infer that the vast majority of patients 
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in our study died from their cancer and not with it. Second, like many studies, we only have 
one measure of 25(OH)D from close to the time of diagnosis. Though we accounted for 
seasonal variability at the time of blood draw, we cannot account for intraindividual changes 
to 25(OH)D levels over follow-up time, including seasonally, during treatment, or after 
treatment is completed. In the absence of taking vitamin D supplementation, healthy adults’ 
25(OH)D levels do not vary dramatically over a few years but tend to decrease notably 
across a decade. (58–60) However, this decrease in 25(OH)D levels tracks with age and does 
not modify the association with all-cause mortality.(61) Few studies have examined the 
impact of cancer treatment on 25(OH)D levels. Breast cancer patients have shown 
significantly decreased 25(OH)D levels after neoadjuvent chemotherapy, but even 
accounting for that change, neither baseline nor post treatment 25(OH)D levels have been 
associated with pathological response to treatment.(62,63) In contrast, another recent 
longitudinal study of melanoma patients found that baseline levels of 25(OH)D were not 
associated with risk of relapse but change in 25(OH)D during follow-up (both increased and 
decreased) was associated with worse prognosis, although they did not report change in 
vitamin D status per specific treatment modality.(64) Our findings cannot rule out that 
trajectories of 25(OH)D levels throughout treatment may be associated with esophageal 
adenocarcinoma survival. Longitudinal studies tracking 25(OH)D levels throughout the 
course of treatment would further inform recommendations for patients.
A third, related, limitation of our study is that the timing of the blood draw in relation to 
cancer diagnosis differed across patients, which means although blood draw occurred close 
to the time of diagnosis, patients were at varying points of their treatment regimen at the 
time of blood draw. This is a common problem in the study of prognostic biomarkers. We 
attempted to address this by considering numerous ways in which the timing of the blood 
draw might have affected measured levels of 25(OH)D. While mean 25(OH)D levels were 
statistically significantly different depending on the treatment patients had received at the 
time of blood draw, the levels across different groups actually did not deviate much from the 
overall population mean, and the timing of blood draw in relation to treatment does not 
appear to have impacted the main results. Moreover, the consistently null findings in almost 
all analysis and the p-values consistently close to 1 support the null hypothesis, and mean 
that potential residual confounding from the above mentioned factors is unlikely to change 
the results of our analyses.
There are several strengths to our study. To our knowledge, this is the largest study to 
examine the effect of 25(OH)D levels as a prognostic factor in esophageal adenocarcinoma, 
and the first to look exclusively at esophageal adenocarcinoma. We were able to consider 
possible effect modifiers and many relevant confounders in addition to the main effect. 
Additionally, our study population demographics are similar to the demographics of 
esophageal adenocarcinoma patients across the United States, supporting generalizability of 
our findings.
Despite the biologic evidence that the vitamin D pathway suppresses tumor progression via 
a number of mechanism and the epidemiologic evidence that higher levels of vitamin D are 
protective against total cancer mortality, the evidence for 25(OH)D serum levels as a marker 
of prognosis of specific cancer sites in humans has been equivocal. We found no evidence 
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that circulating 25(OH)D levels are associated with overall survival among esophageal 
adenocarcinoma patients, accounting for a number of potential confounders and effect 
modifiers. A recent trial of vitamin D supplementation found those taking supplementation 
had reduced risk of cancer mortality, and the association was strongest after excluding the 
first 2 years of follow-up after cancer diagnosis.(49) Our consistently null associations 
between serum 25(OH)D levels and overall survival among esophageal adenocarcinoma 
patients may indicate that the aggressive nature of this cancer precludes any potential 
protective benefits of vitamin D.
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Figure 1: Flow chart of the study population:
Figure 1 shows a flow chart of patients included in the study and patients who were 
excluded from analysis.
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Figure 2: Kaplan-Meier survival curve by quartiles of 25(OH)D accounting for month of blood 
draw
Figure 2 shows the Kaplan-Meier survival curve, and corresponding Logrank test, of overall 
surival among esophageal adenocarcinoma patients stratified by quartiles of serum 25(OH)D 
levels, categorized accounting for month of blood draw. Quartile 1 represents the highest 
25(OH)D levels, and quartile 4 includes the lowest 25(OH)D levels.
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Table 1:
Study population characteristics
Serum Available (N=495) Serum Not Available (N=92)
Men 440 (88.9%) 73 (79.4%)
Age 63.2 ± 11.0 64.8 ± 10.9
Race
White 461 (93.1%) 85 (92.4%)
Black 2 (0.4%)
Hispanic 6 (1.2%) 2 (2.2%)
Asian 4 (0.8%)
Native American 5 (1.0%) 1 (1.1%)
Former Smoker 313 (63.2%) 62 (67.4%)
Current Smoker 73 (14.8%) 13 (14.2%)
BMI (kg/m2) 27.4 ± 5.0 27.9 ± 5.9
Stage
Lymph node negative (I-IIA) 157 (31.7%) 30 (32.6%)
Lymph node positive (IIA-IVA) 240 (48.5%) 48 (52.2%)
Metastatic (IVB) 98 (19.8%) 14 (15.2%)
Treatmenta
Surgery 358 (72.3%) 66 (71.7%)
Chemotherapy 392 (79.2%) 66 (71.7%)
Radiation 351 (70.9%) 60 (65.2%)
25(OH)D (ng/mL) 20.7 ± 10.2
Death 377 (76.2%) 62 (67.4%)
Values represent number(%) or mean ± SD.
a
Treatment values are not mutually exclusive.
1 patient with vitamin D available was missing information on treatment. Among participants with serum available, information was missing about 
race (N=16), smoking status (N=3), BMI (N=18), and treatment modality (N=1). Among participants with serum not available, information was 
missing about race (N=4) and BMI (N=2).
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Table 2:
Serum levels of 25(OH)D and overall survivala among EA patients (N=476)
25(OH)D Quartilesb N deaths/patients Hazard Ratio 95% CI p-value
1 (highest) 90/114 REF
2 82/120 0.90 (0.67, 1.23) 0.51
3 95/124 1.03 (0.76, 1.38) 0.87
4 (lowest) 93/118 0.98 (0.72, 1.33) 0.90
Global p-value=0.86
25(OH)D Clinical Cut Pointsc
≥40 ng/mL (≥100 nmol/L) 14/16 REF
30–40 ng/mL (75–100 nmol/L) 31/39 1.29 (0.68, 2.47) 0.44
20–30 ng/mL (50–75 nmol/L) 124/177 0.98 (0.55, 1.73) 0.93
10–20 ng/mL(25–50 nmol/L) 159/201 1.22 (0.69, 2.16) 0.49
<10 ng/mL (<25 nmol/L) 32/43 0.98 (0.50, 1.92) 0.96
Global p-value=0.32
25(OH)D Continuous (ng/ml)c 1.00 (0.99, 1.01) 0.54
aOverall survival was calculated as time between date of blood draw and date of death or date last known to be alive.
b
Estimates come from model that additionally adjusted for age, sex, smoking status, BMI categories, year of diagnosis, time between diagnosis and 
blood draw, chemotherapy, radiation, time-dependent surgery, and baseline treatment was stratified by tumor stage by lymph node status. Quartiles 
of vitamin D were determined accounting for month of blood draw.
c
Estimates come from model that additionally adjusted for age, sex, smoking status, BMI categories, season of blood draw, year of diagnosis, time 
between diagnosis and blood draw, chemotherapy, radiation, time-dependent surgery, and baseline treatment was stratified by tumor stage by lymph 
node status.
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Table 3:
Serum levels of 25(OH)D and overall survivala among EA patients, stratified by clinical stage (N=476)
25(OH)D Quartilesb N deaths/patients HRc 95% Confidence Limits
Lymph node negative at diagnosis
Quartile 1 (Highest) 19/28 REF
Quartile 2 21/41 0.93 0.49 1.76
Quartile 3 25/41 0.95 0.51 1.74
Quartile 4 (lowest) 27/41 1.00 0.55 1.82
Lymph node positive at diagnosis
Quartile 1 (Highest) 44/59 REF
Quartile 2 39/57 0.95 0.61 1.47
Quartile 3 48/60 1.12 0.74 1.70
Quartile 4 (lowest) 42/53 1.19 0.77 1.83
Metastatic at diagnosis
Quartile 1 (Highest) 27/27 REF
Quartile 2 22/22 0.80 0.45 1.42
Quartile 3 22/23 0.95 0.52 1.73
Quartile 4 (lowest) 24/24 0.69 0.39 1.24
aOverall survival was calculated as time between date of blood draw and date of death or date last known to be alive.
bQuartiles of vitamin D were determined accounting for month of blood draw.
c
Model adjusted for the main effect of vitamin D, age, sex, smoking status, the main effect of BMI categories, year of diagnosis, chemotherapy, 
radiation, time-dependent surgery, and baseline treatment, and baseline hazard was stratified by tumor stage by lymph node status.
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Table 4:
Serum levels of 25(OH)D and overall survivala among EA patients, stratified by BMI (N=469)
25(OH)D Quartilesb N deaths/patients HRc 95% Confidence Limits
BMI (≥18.5 and <25)
Quartile 1 (Highest) 30/37 REF
Quartile 2 26/38 0.68 0.40 1.17
Quartile 3 34/38 1.08 0.65 1.79
Quartile 4 (lowest) 33/36 0.74 0.44 1.25
BMI (≥25 and <30)
Quartile 1 (Highest) 45/56 REF
Quartile 2 37/51 0.98 0.62 1.54
Quartile 3 37/50 0.83 0.53 1.29
Quartile 4 (lowest) 32/45 1.14 0.71 1.82
BMI (≥30)
Quartile 1 (Highest) 15/21 REF
Quartile 2 18/29 1.32 0.65 2.67
Quartile 3 23/34 1.51 0.77 2.96
Quartile 4 (lowest) 25/34 1.22 0.63 2.36
aOverall survival was calculated as time between date of blood draw and date of death or date last known to be alive.
bQuartiles of vitamin D were determined accounting for month of blood draw.
c
Model estimates adjusted for the main effect of vitamin D, age, sex, smoking status, the main effect of BMI categories, year of diagnosis, 
chemotherapy, radiation, time-dependent surgery, and baseline hazard was stratified by tumor stage by lymph node status.
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2020 February 01.
